NPHC (Nutra Pharma) Total Debt per Share: $0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nutra Pharma Total Debt per Share?

Nutra Pharma NPHC Total Debt per Share is $0.00 as of Mar. 2026. The stock has 5 warning signs investors should review.

$0.00 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Nutra Pharma's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.00.

Nutra Pharma Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Nutra Pharma's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nutra Pharma Total Debt per Share Chart

Nutra Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nutra Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nutra Pharma Total Debt per Share Calculation

Nutra Pharma's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.14+9.62)/7,099.73
=0.00

Nutra Pharma's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.14+9.87)/7,159.73
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.00 mean?
Nutra Pharma (NPHC) has a Total Debt per Share of $0.00 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Nutra Pharma and its competitors.
Is Nutra Pharma's Total Debt per Share too high?
Nutra Pharma's current Total Debt per Share is $0.00.
How does Nutra Pharma's Total Debt per Share compare to UPC and CBIH?
Nutra Pharma's Total Debt per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Nutra Pharma and its competitors. Nutra Pharma's current Total Debt per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutra Pharma stock overvalued right now?
Nutra Pharma (NPHC) has a current Total Debt per Share of $0.00. The current Total Debt per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Nutra Pharma (NPHC), the current Total Debt per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nutra Pharma Business Description

Address 6400 Park of Commerce Boulevard, Suite 1B, Boca Raton, FL, USA, 33487
Nutra Pharma Corp operates as a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases, and pain. It is focused on homeopathic and drug discovery research and clinical development, and has developed four homeopathic drugs for the relief of pain: Nyloxin and Nyloxin Extra Strength, Pet Pain-Away, Equine Pain-Away, and Luxury Feet. Additionally, the company has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases; and RPI-MN, to treat viral diseases, including HIV/AIDS and Herpes. Nutra Pharma produces, markets, and distributes its branded products both domestically and internationally.